The Global Multiple Sclerosis Therapeutics Market, by Drug Class (Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents and Others), by Route of Administration (Oral and Injection), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 19,653.7 million in 2016 and is projected to exhibit a CAGR of 2.5% over the forecast period (2017 – 2025).
The multiple sclerosis therapeutics market is expected to gain significant traction during the forecast period with the expected launch of potential pipeline candidates. The market players are focusing on drug discovery to strengthen the pipeline drug development and accelerating delivery of new treatments to patients living with the condition, thus augmenting the multiple sclerosis therapeutics market in the foreseeable period. For instance, in 2017, TG Therapeutics, Inc., entered into an agreement with the U.S. Food and Drug Administration (FDA) regarding the Special Protocol Assessment (SPA) of phase 3 clinical trials for TG-1101, an anti-D20 monoclonal antibody for the treatment of relapsing forms of multiple sclerosis. Also, in 2017, Antisense Therapeutics announced the proceeding of its Phase 2b clinical trials as the U.S. FDA lifted the clinical hold for the drug candidate ATL1102. ATL1102 is indicated for relapsing remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS). The introduction of novel and highly efficient B-cell targeted therapies is expected to fuel the market as they prove to be a promising therapy for multiple sclerosis treatment. For instance, in 2017, the FDA approved Genentech’s Ocrevus (ocrelizumab) a humanized monoclonal antibody targeting B-cells with CD20 molecule. Ocrevus is the only therapy approved for both relapsing and primary progressive forms of multiple sclerosis.
Browse 35 Market Data Tables and 40 Figures spread through 148 Pages and in-depth TOC on “Multiple Sclerosis Therapeutics Market”- Global Forecast to 2025, by Drug Class (Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents and Others), by Route of Administration (Oral and Injection), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa)
To know the latest trends and insights prevalent in the multiple sclerosis therapeutics market, click the link below:
https://www.coherentmarketinsights.com/market-insight/multiple-sclerosis-therapeutics-market-1310
Market players are also trying on inorganic route for growth in the global multiple sclerosis therapeutics market. For instance, in 2011, Sanofi SA acquired Genzyme for a whooping US$ 20.1 Bn, thus gaining rights for Genzyme’s injectable drug Lemtrada which was FDA approved in 2014, dfor the treatment of relapsing remitting multiple sclerosis. In 2015, Actelion Ltd., initiated Phase III development with ponesimod- a selective S1P1 receptor modulators in patients suffering from relapsing multiple sclerosis. Actelion Ltd. was acquired by Johnson & Johnson in 2017, gaining access to the pipeline drug candidate, thus expanding product portfolio. In 2017, Sanofi SA collaborated with Principia Biopharma, Inc., for the development of potential multiple sclerosis oral drug candidate PRN2246. PRN2246 is a tyrosine kinase inhibitor which is currently in clinical development. The collaborative partnerships with healthcare providers, patients and researchers is expected to establish ways in order to share the findings for improving care for people with MS, thus bringing novel therapeutics with enhanced safety profiles in the market. For instance, in 2014, Accelerated Cure Project for MS, Feinstein Kean Healthcare and Complex Adaptive Systems at Arizona State University came together to create iConquerMS. iConquerMS was launched to enable secure collection of large amounts of health data form people living with MS, thereby providing updates for the researchers to improve diagnosis and optimize treatment.
Key Takeaways of the Multiple Sclerosis Therapeutics Market:
- The global multiple sclerosis therapeutics market is expected to exhibit a CAGR of 2.5% over the forecast period, owing to the presence of high potential market and increasing government initiatives to curb the disease in Asia Pacific, Latin America, the Middle East, and Africa
- Among drug class, corticosteroids segment holds a dominant position attributed to the advantages offered by the drugs that include lower risk of side effects and higher number of drug candidates in the product portfolio of the manufacturers
- Among route of administration, injectable segment holds a dominant position in the multiple sclerosis therapeutics market, owing to the higher recommendations of the doctors as the drugs administered by this route have instant mode of action
- Some of the major players operating in the global multiple sclerosis therapeutics market include Novartis AG, Teva Pharmaceuticals Industries Ltd. Sanofi Genzyme, Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co. Inc. and AbbVie, Inc.
